A phase 3, double-blind, randomised, parallel-group, placebo-controlled study of oral weekly alendronate for the prevention of androgen deprivation bone loss in nonmetastatic prostate cancer: the Cancer and Osteoporosis Research with Alendronate and Leuprolide (CORAL) study. [electronic resource]
Producer: 20130924Description: 927-35 p. digitalISSN:- 1873-7560
- Absorptiometry, Photon
- Administration, Oral
- Aged
- Aged, 80 and over
- Alendronate -- administration & dosage
- Alkaline Phosphatase -- blood
- Analysis of Variance
- Androgen Antagonists -- administration & dosage
- Antineoplastic Agents, Hormonal -- administration & dosage
- Biomarkers -- blood
- Bone Density -- drug effects
- Bone Density Conservation Agents -- administration & dosage
- Canada
- Chi-Square Distribution
- Collagen Type I -- blood
- Double-Blind Method
- Drug Administration Schedule
- Hip Joint -- diagnostic imaging
- Humans
- Injections, Intramuscular
- Leuprolide -- administration & dosage
- Lumbar Vertebrae -- diagnostic imaging
- Male
- Middle Aged
- Osteoporosis -- blood
- Patient Selection
- Peptides -- blood
- Predictive Value of Tests
- Prostatic Neoplasms -- drug therapy
- Time Factors
- Treatment Outcome
No physical items for this record
Publication Type: Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.